Clinical Trial

The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy

Study acronym: ROSARIO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Study rationale: Viral infections, such as CMV, are a risk factor for TA-TMA (transplantation-associated TMA). Viral infections increase interferon (IFN) levels and high IFN levels are associated with thrombotic microangiopathy (TMA). IFNs contribute to TMA pathogenesis through suppression of VEGF transcription. Disruption of the VEGF signalling pathway in the kidney is associated with TMA. Primary objective: To determine the association between IFN levels and the development of biopsy-proven or clinically diagnosed TA-TMA. Secondary objective(s): To explore the relationship between complement activation and IFN in patients with TMA. To explore if high IFN levels are associated with low VEGF-A levels. Endpoint: The study aims to investigate the role of IFN in the pathogenesis of secondary thrombotic microangiopathy (focusing on patients with TA-TMA). It seeks to clarify whether IFN, next to complement dysregulation, is a driver of endothelial damage and TMA in these patients.
Trial Details
NCT Number NCT07705789
Lead Sponsor Sofie Dhaese
Collaborators: AZ Sint-Jan AV, University Hospital, Ghent, Universitaire Ziekenhuizen KU Leuven
Conditions Thrombotic Microangiopathies
Enrollment 40 participants
Start Date 2026-09-01
Primary Completion 2031-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15